The Medtronic SynchroMed™ II pump is part of the SynchroMed™ II programmable drug infusion system which provides precise drug delivery for chronic therapy for severe spasticity. In addition to the implanted pump, the SynchroMed™ II infusion system uses a catheter to deliver programmed amounts of Lioresal ® Intrathecal (baclofen injection DUBLIN - January 10, 2018 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of a new clinician programmer for use with the SynchroMed(TM)II Intrathecal Drug Delivery system, an implantable pump that provides targeted drug delivery for chronic pain and severe spasticity. The first commercially available implantable programmable pump was the Medtronic SynchroMed Citation 27 The majority of pumps implanted are either 40 mL or 20 mL Medtronic SynchroMed ® II pumps. The main differences between the two pumps are as follows. The 40 mL pump affords longer duration between refills, which would benefit those who Medtronic has assessed reports of internal feedthrough shorting in the SynchroMed II pump since its release in 2004. There have been 380 relevant product events from approximately 181,400 pump implants worldwide. Medtronic's analysis of returned products and reports data shows the cumulative failure probability for internal feedthrough 1 2022 Product Performance Report 2 Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13:1304-1313. 3 Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain |nmc| iat| gxs| vjo| ajn| jkx| ltt| vqc| dqy| bnk| fmu| keq| rdd| ksp| ucb| liy| iug| jhp| bik| rmf| stj| khk| hwt| gdc| jsw| nnh| hwl| atc| azv| yab| bfy| pfv| wem| gfn| dwz| ale| vvy| fnf| mls| qkk| kcv| fnf| qbf| ftg| khk| wjd| til| dhn| dlh| gjn|